Alkem Laboratories has announced the incorporation of a wholly owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE. The new entity has been established to facilitate the export of Alkem Laboratories‘ products to African, South East Asian, and non-UAE markets.
Alkem Pharma Trading FZCO has an authorised share capital of AED 36,70,000, divided into 3,67,000 equity shares of AED 10 each. The subscribed capital matches the authorised capital, indicating full subscription of the shares. As a wholly owned subsidiary, Alkem Pharma is a related party of Alkem Laboratories, and the transaction is conducted at arm’s length.
The subsidiary operates within the pharmaceuticals industry and aims to expand Alkem Laboratories’ reach in international markets. The incorporation of Alkem Pharma Trading FZCO took place on 27th March 2026, and the Certificate of Formation was received from the Dubai Airport Free Zone Authority on 13th April 2026.
The establishment of this subsidiary is a strategic move by Alkem Laboratories to enhance its global footprint and cater to the growing demand for its products in emerging markets. The company has opted for a cash consideration for the acquisition, subscribing to 3,67,000 equity shares at AED 10 each, amounting to a total of AED 3,670,000.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).